SFDA Signs MoU with UK’s MHRA to Support Innovation, Accelerate Patient Access to Treatments
The Saudi Food and Drug Authority (SFDA) has signed a memorandum of understanding with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to enhance the evaluation of innovative therapies and facilitate timely patient access while maintaining high standards of safety, quality, and efficacy. The signing took place on the sidelines of the DIA–MHRA Global Summit, held in London on November 16–17, 2026. The MoU was signed by CEO of the SFDA Dr. Hisham Aljadhey and Chief Executive of the MHRA Lawrence Tallon, in the presence of MHRA Chair Prof. Anthony Harnden. Following the signing, the two sides held a bilateral meeting to discuss cooperation priorities in light of the latest scientific and regulatory developments.
Building on existing collaboration and a shared commitment to keeping pace with medical innovation, the MoU covers the assessment of rare disease treatments, advanced therapies, and biotechnology products. It also includes exchanging knowledge on applying artificial intelligence, modeling, and computer simulation in clinical studies and trials. This cooperation helps provide developers with greater clarity on regulatory requirements early in the development process, particularly when developing treatments for patients with limited therapeutic options.
Under the MoU, SFDA and MHRA will exchange information and expertise in medical product registration and assessment, Good Manufacturing Practices (GMP), quality management systems, product testing and analysis, and supply chain monitoring.
Together, these efforts support the safety of medical products in the Saudi and UK markets and strengthen both sides' ability to identify and mitigate associated risks. This cooperation supports Saudi Vision 2030 goals to improve quality of life by facilitating patient access to safe and effective treatments. It also aligns with the National Biotechnology Strategy’s focus on developing national capabilities and fostering sector innovation through scientific exchange and advanced regulatory assessment methods for biological medicines and innovative therapies.



